Year None202320222021202020192018201720162015201420132012 03.02.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 03.01.2023 Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results 03.01.2023 Iveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER Trials 02.28.2023 Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference 02.22.2023 Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023 02.16.2023 Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy 02.02.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.04.2023 Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.03.2023 Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directors 12.20.2022 Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »